|
|
|
| Effects of the different doses of femostonon for treating patients with menopausal syndrome on their lipid metabolism and endocrine function |
| The Seventh People's Hospital of Zhengzhou, Zhengzhou, Henan Province, 450006 |
|
|
|
|
Abstract To investigate the effects of the different doses of femostonon for treating patients with menopausal syndrome on their lipid metabolism and endocrine function. Methods: 106 patients with menopausal syndrome treated in hospital were selected and were randomly divide into two groups (53 cases in each group) from August 2021 to May 2023. The patients in group A were given the conventional dose of femoston for treatment and the patients in group B were given the low dose of femoston for treatment. The score of Kuppeman menopause rating scale, the levels of the blood lipids and sex hormones, and the adverse reactions rate of the patients were compared between two groups. Results: The Kupperman score of the patients in both groups had decreased significantly, and which (8.61±2.13 points) of the patients in group A were significantly lower than that (9.57±2.24 points) of the patients in group B (P<0.05). The levels of the total cholesterol, triglyceride, low density lipoprotein cholesterol of the patients in the two groups after treatment had decreased significantly, but the high-density lipoprotein cholesterol level of the patients in the two groups after treatment had increased significantly (P<0.05), but all of which of the patients had no significant differences between the two groups (P>0.05). After treatment, the estradiol level of the patients in both groups had increased significantly, but which (40.58±3.25ng/L) of the patients in group A was significantly higher than that (34.16±3.12ng/L) of the patients in group B. The levels of follicle-stimulating hormone (37.52±4.28 mU/ml) and luteinizing hormone (21.04±2.68mU/ml) of the patients in group A were significantly lower than those (44.67±4.86 mU/ml and 25.14±2.77mU/ml) of the patients in group B (all P<0.05). The incidence of adverse reactions (17.0%) of the patients in group A had no significantly different from that (9.4%) of the patients in group B (P>0.05). Conclusion: The different doses of femostonon for treating patients with menopausal syndrome can effectively improve their clinical symptoms, abnormal lipid metabolism and endocrine disorders, but the conventional dose of femoston has the better efficacy without increasing the risk of adverse reactions.
|
|
|
|
|
|
|
|
|
